April 2026 is making a splash in Milwaukee for being the wettest month of April on record, according to National Oceanic and Atmospheric Administration data. Barely halfway through the month, this ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Attribution researches the influence of climate change on local weather and impacts. We issues alerts in many instances when the Climate Shift Index identifies a notable extreme weather event around ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...

REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted ...

Real-time tools, visuals, and other resources to quantify the role of climate change in weather events. Alerts We issues alerts in many instances when the Climate Shift Index identifies a notable ...

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS ...

THAN WHAT HE WAS 1015 YEARS AGO. COULDN’T HAVE SAID IT BETTER MYSELF I AGREE. YEAH, LET’S TALK ABOUT THE WEATHER. THAT’S NOT INCREDIBLE. ANOTHER IMPACT DAY. IF ONLY IT COULD BE AS GOOD AS THE BBC IS.

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...

UP. A LOT OF POWER AND ENERGY, ONE AFTER THE OTHER. IT WAS LOUD. IT WAS RUMBLING LAST NIGHT. NOW WE KIND OF HAVE A DEEP BREATH AS THE SUN COMES UP BEHIND US. AND YOU CAN KIND OF TAKE THAT DEEP BREATH ...